September 2025 – The global plasma-derived products market, valued at USD 29.86 billion in 2024, is projected to grow to USD 51.54 billion by 2031, expanding at a CAGR of 8.1% during the forecast period, according to a new market study. Growth is fueled by the rising prevalence of chronic and rare diseases, increased adoption of immunoglobulin therapies, and advancements in plasma fractionation technologies.

Get free sample of this report at :  https://www.24lifesciences.com/download-sample/3367/plasma-derived-products-market-market 

Plasma-derived products are essential biologics derived from human plasma, including immune globulins, coagulation factors, albumin, and specialized proteins, used to treat life-threatening conditions such as hemophilia, primary immunodeficiency, and autoimmune disorders. The immune globulin segment dominated with a 51% share in 2023, underscoring its critical role in treating immune-related diseases.

Market Dynamics

• Drivers:

  • Rising cases of hemophilia, primary immunodeficiency, and hereditary angioedema.

  • Technological innovations in plasma fractionation improving yield and safety.

  • Expanding plasma collection networks across emerging markets.

• Opportunities:

  • Rapid growth in Asia-Pacific and Latin America with increasing healthcare spending.

  • Expansion into new therapeutic areas, including neurology, infectious diseases, and wound healing.

• Trends:

  • Strong demand for immunoglobulin therapies for autoimmune and neurological disorders.

  • Expansion of plasma collection centers, particularly in China and North America.

Regional Insights

• North America leads the global market with 40% share, supported by advanced infrastructure, robust plasma collection networks, and leading industry players such as CSL and Grifols.

• Europe holds 24% share, benefiting from strict regulatory frameworks and strong demand for immune globulins and coagulation factors, though supply chain constraints remain a challenge.

• Asia-Pacific is the fastest-growing region, with China, Japan, and South Korea driving growth through healthcare investments, rising diagnosis rates, and expanding local production capabilities.

Competitive Landscape

Key players in the plasma-derived products market include:
Takeda, CSL, Grifols, Octapharma, Kedrion, LFB Group, Biotest, BPL, RAAS, CBPO, Hualan Bio, Tiantan Bio, Shuanglin Bio, Boya Bio, Yuanda Shuyang, Weiguang Bio, Nanyue Bio, and KM Biologics.
These companies are expanding production capacity, advancing plasma fractionation technologies, and diversifying product portfolios to meet surging global demand.
 
Get free sample of this report at :  https://www.24lifesciences.com/download-sample/3367/plasma-derived-products-market-market 

https://24lifesciencesid3.blogspot.com/2025/09/hydroxycarbamide-market-regional.html

https://hallbook.com.br/blogs/749142/Hydroxycarbamide-Market-Regional-Analysis-Demand-Analysis-and-Competitive-Outlook-2025

https://lifesciencesid.stck.me/post/1283985/Hydroxycarbamide-Market-Regional-Analysis-Demand-Analysis-and-Competitive-Outlook-2025-2032

https://blogvisit.freeadstime.org/visitors-and-members.php